Citation Impact
Citing Papers
Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors I karos and A iolos via modulation of the E 3 ubiquitin ligase complex CRL 4 CRBN
2013
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
2013 Science
Comprehensive computational design of ordered peptide macrocycles
2017 StandoutScienceNobel
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Evolution of the Cancer Stem Cell Model
2014 Standout
Expansive discovery of chemically diverse structured macrocyclic oligoamides
2024 StandoutScienceNobel
Degradation of proteins by PROTACs and other strategies
2019
Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
2020
Myeloid-derived suppressor cells coming of age
2018 Standout
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
2012
Molecular mechanisms of cereblon-based drugs
2019
Regulation and Functions of the ER-Associated Nrf1 Transcription Factor
2022 StandoutNobel
Circulating immune cell phenotype can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma
2016
Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation
2014 StandoutNobel
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System
2014
Cereblon modulators: Low molecular weight inducers of protein degradation
2019
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
The single-cell transcriptional landscape of mammalian organogenesis
2019 StandoutNature
NEDD8 nucleates a multivalent cullin–RING–UBE2D ubiquitin ligation assembly
2020 Nature
Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma
2014
Phenotypic screening with target identification and validation in the discovery and development of E3 ligase modulators
2021
Guidance of regulatory T cell development by Satb1-dependent super-enhancer establishment
2016 StandoutNobel
Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma
2013
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Coming of age: ten years of next-generation sequencing technologies
2016 Standout
The diverse roles of IRF4 in late germinal center B‐cell differentiation
2012
Development of targeted protein degradation therapeutics
2019
Comprehensive analysis of loops at protein-protein interfaces for macrocycle design
2014
Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position
2013 Standout
Transcription factor Ikzf1 associates with Foxp3 to repress gene expression in Treg cells and limit autoimmunity and anti-tumor immunity
2024 StandoutNobel
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
2015
Postallograft lenalidomide induces strong NK cell–mediated antimyeloma activity and risk for T cell–mediated GvHD: Results from a phase I/II dose-finding study
2012
Emerging New Concepts of Degrader Technologies
2020
Multispecific drugs herald a new era of biopharmaceutical innovation
2020 Nature
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
2020
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
2009
Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment
2014 Standout
ATAC-see reveals the accessible genome by transposase-mediated imaging and sequencing
2016 StandoutNobel
Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations
2019
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
2021
Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs
2014
Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
2019
Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway
2021 StandoutNobel
Organoid single-cell genomic atlas uncovers human-specific features of brain development
2019 StandoutNatureNobel
Phenotypic screening in cancer drug discovery — past, present and future
2014
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
2012
Peptidic degron in EID1 is recognized by an SCF E3 ligase complex containing the orphan F-box protein FBXO21
2015 StandoutNobel
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
2020
Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway
2019
Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity
2017 StandoutNobel
Peptidic degron for IMiD-induced degradation of heterologous proteins
2019 StandoutNobel
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Waste disposal—An attractive strategy for cancer therapy
2017 Science
A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos
2017
Resistance to proteasome inhibitors and other targeted therapies in myeloma
2018
Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1
2016 StandoutNobel
Brazilian green propolis promotes TNFR2 expression on regulatory T cells
2021 StandoutNobel
High expression of cereblon (CRBN ) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone
2013
Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
2018
Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality
2019
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
2011
ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐Wide
2015 Standout
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders
2017
Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia
2021 StandoutNobel
Multiple Myeloma
2011 Standout
Stapled β-Hairpins Featuring 4-Mercaptoproline
2021 StandoutNobel
Lenalidomide efficacy in activated B ‐cell‐like subtype diffuse large B ‐cell lymphoma is dependent upon IRF 4 and cereblon expression
2012
Works of Derek Mendy being referenced
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
2012
Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma
2016
Lenalidomide downregulates the cell survival factor, interferon regulatory factor‐4, providing a potential mechanistic link for predicting response
2011
UBE2G1 governs the destruction of cereblon neomorphic substrates
2018
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity
2013
CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML)
2019
Direct Binding with Cereblon Mediates the Antiproliferative and Immunomodulatory Action of Lenalidomide and Pomalidomide
2011
Stimulation of T Cells by Lenalidomide Involves Putative Lenalidomide Binding Proteins CD3-Epsilon-Associated Protein and GDP-Mannose Pyrophosphorylase a
2008
Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function
2010
CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells
2019
Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy
2008